{
    "clinical_study": {
        "@rank": "8114", 
        "arm_group": [
            {
                "arm_group_label": "Stablor", 
                "arm_group_type": "Experimental", 
                "description": "dietary supplement Stablor"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "dietary supplement Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the impact of the intake of a dietary supplement\n      STABLOR\u2122 on the change of the abdominal visceral fat mass in patients with a metabolic\n      syndrome."
        }, 
        "brief_title": "Effect of Stablor on Visceral Fat Loss in Patients With a Metabolic Syndrome", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Metabolic Syndrome", 
        "condition_browse": {
            "mesh_term": "Metabolic Syndrome X"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  With a Body Mass Index (BMI) more than or equal to 25 kg/m\u00b2 and less than 40 kg/m\u00b2,\n\n          -  With a metabolic syndrome characterized by a a waist circumference of more than 94 cm\n             for the males (90 cm for South-Asians, Chinese and Japanese) and more than 80 cm for\n             the females, and at least 2 of the following criteria :\n\n               -  Arterial Blood pressure > or = 130 mmHg (systolic) and/or more than or equal to\n                  85 mmHg (diastolic) or stabilized with treatment for at least 6 months,\n\n               -  Fasting glycemia > or = 1 g/L or 5.6 mmol/L or  stabilized with treatment for at\n                  least 6 months and non-diabetic < 1.26 g/L,\n\n               -  Triglycerides > or = 1.5 g/L or 1.71 mmol/L or  stabilized with treatment for at\n                  least 6 months,\n\n               -  HDL Cholesterol <0.40 g/L or 1.03 mmol/L (males) and  <0,5 g/l or 1.29 mmol/L\n                  (females) or  stabilized with treatment for at least 6 months.\n\n        Exclusion Criteria:\n\n          -  Pregnant (positive pregnancy test at the selection visit or breast-feeding woman,\n\n          -  Woman of childbearing potential without an efficient contraception method,\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in the clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "118", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755104", 
            "org_study_id": "RCM-EFF-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Stablor", 
                "intervention_name": "Stablor", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Laval", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "Institut des Nutraceutiques et des Aliments Fonctionnels (INAF)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "Institut CardioMetabolisme et Nutrition (ICAN)"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "France"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Double-blind Placebo Controlled Trial on the Effect of Stablor\u2122 on the Abdominal Visceral Fat Mass Loss in Patients With a Metabolic Syndrome", 
        "overall_official": {
            "affiliation": "Institut CardioMetabolisme et Nutrition (ICAN)", 
            "last_name": "Karine Clement, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in visceral fat area assessed by computerized tomodensitometry", 
            "safety_issue": "No", 
            "time_frame": "From baseline to Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755104"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Changes in selected cardiometabolic risk factors : anthropometric and physical measurements, biomarkers", 
                "safety_issue": "No", 
                "time_frame": "from baseline to end of study"
            }, 
            {
                "measure": "Quality of life, psychological and behavioral changes", 
                "safety_issue": "No", 
                "time_frame": "From baseline to end of study"
            }
        ], 
        "source": "Laboratoires Nutrition et Cardiometabolisme", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Laboratoires Nutrition et Cardiometabolisme", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}